AJP Winter 2024 | The Future of Hyperlipidemia Treatment: New Non-Statin Medications is organized by Arizona Pharmacy Association (AzPA).

Released: 2024-01-09
Expires: 2027-01-09

Learning Objectives:

Describe the mechanisms of action of new non-statin medications, including PCSK9 monoclonal antibodies(mAbs), inclisiran, and bempedoic acid.
Identify patients who may benefit from non-statin medications.
List potential adverse effects associated with non-statin medications.
Describe recent changes in recommendations for the 2022 American College of Cardiology (ACC) expert consensus discussion pathway in regard to the role of PCSK9 mAbs, inclisiran, and bempedoic acid.
List potential drug-drug interactions associated with bempedoic acid